论文部分内容阅读
目的:探讨重组人类基因促红细胞生成素(rhEPO)对早产儿脑损伤保护作用及临床疗效。方法:选择2012年1月至2014年5月我院出生并收治的76例早产儿为研究对象。将76例患儿随机分为对照组与观察组各38例。两组患儿均在出生后给予常规治疗,观察组自出生起即在基础治疗上加用rhEPO。对所有病例严格随访至出生后1岁。结果:两组患儿出生时的新生儿神经行为测定(NBNA)评分分别为28.72±5.56与29.29±5.16,两组间比较未见显著性差异(P>0.05),经治疗12个月观察组NBNA评分为39.32±7.58,对照组为35.87±6.93,两组均较治疗前有了显著提高,组间比较观察组评分高于对照组,差异具有显著性(P<0.05)。对两组进行Gesell发育量表评价,观察组早产儿的精细动作、适应能力及社交行为得分均高于对照组,差异具有统计学意义(P<0.05)。观察组共11例早产儿表现为神经系统影像学异常,发生率为28.9%,对照组为21例,发生率为55.3%,组间比较观察组异常率低于对照组,差异具有显著性(P<0.05)。结论:rhEPO对神经组织具有直接的保护和营养作用,对早产儿使用rhEPO可有效改善其预后,降低脑损伤后遗症的发生,可作为临床治疗早产儿脑损伤的一种新方法加以推广应用。
Objective: To investigate the protective effect of recombinant human erythropoietin (rhEPO) on brain injury in premature infants and its clinical efficacy. Methods: From January 2012 to May 2014, 76 preterm infants born and treated in our hospital were selected as the study subjects. 76 children were randomly divided into control group and observation group, 38 cases each. Both groups of children were given conventional treatment after birth, the observation group from the time of birth that is, rhEPO added in the basic treatment. All patients were strictly followed up to 1 year after birth. Results: Neonatal neurobehavioral test (NBNA) at birth were 28.72 ± 5.56 and 29.29 ± 5.16, respectively. There was no significant difference between the two groups (P> 0.05). After treatment for 12 months, the observation group The score of NBNA was 39.32 ± 7.58 in the control group and 35.87 ± 6.93 in the control group. The score of NBNA was significantly higher than that of the control group before treatment. The difference was significant (P <0.05). The Gesell development scale was evaluated in both groups. The fine motor activity, adaptability and social behavior scores of the observed group were higher than those of the control group (P <0.05). A total of 11 preterm infants in the observation group showed neurological abnormalities, with a rate of 28.9% and 21 cases in the control group, with a prevalence of 55.3%. The abnormal rate of the observation group was lower than that of the control group P <0.05). CONCLUSION: rhEPO has a direct protective and nutritional effect on nerve tissue. Using rhEPO in preterm infants can effectively improve its prognosis and reduce the occurrence of sequelae of brain injury. It can be used as a new method for clinical treatment of brain injury in premature infants.